Balaxi Pharmaceuticals Share Price Today | Stock Price & Balaxi Pharmaceuticals Share Screener
As of October 5, 2026, the live Balaxi Pharmaceuticals share price (NSE: BALAXI) is ₹22.77, up 1.92% from the previous close, with shares trading between ₹22.06 and ₹23.05 in today's trading session, and a 52-week range of ₹15.67–₹43.28. Check BALAXI 52-week performance for the annual price range and momentum. Use the Balaxi Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Balaxi Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹74 and net income of ₹1, with EBITDA of ₹3.
Balaxi Pharmaceuticals Share Price Chart
Track the current stock price of Balaxi Pharmaceuticals with an interactive chart. Analyse BALAXI share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Balaxi Pharmaceuticals stock quote in one place.
The quote of ₹22.77 sits between the 52-week low of ₹15.67 and the 52-week high of ₹43.28, and the latest session moved 1.92% from the previous close.
Balaxi Pharmaceuticals Company Profile - Fundamental Screener
Screen Balaxi Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BALAXI shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE618N01022.
Company Details
Classification
Identifiers and Leadership
Balaxi Pharmaceuticals Balance Sheet Screener
Screen BALAXI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹337, up from ₹310 in 2025.
Latest statistics put total assets at ₹337 and shareholder funds at ₹249, with a leverage ratio of 0.23.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 337 | 310 | 258 | 240 | 177 | 100 | 36 | 6 |
| Current Assets | 251 | 243 | 210 | 194 | 141 | 94 | 35 | 6 |
| Fixed Assets | 82 | 41 | 41 | 41 | 29 | 2 | 0 | 0 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 26 | 24 | 3 | 4 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 249 | 232 | 201 | 183 | 113 | 65 | 28 | 4 |
| Share Capital | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 3 |
| Reserves & Surplus | 238 | 221 | 187 | 162 | 103 | 55 | 18 | 1 |
Balaxi Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Balaxi Pharmaceuticals income statement and profit fundamentals. Analyze BALAXI quarterly results. Balaxi Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹74 and net profit was ₹1, equal to earnings per unit of ₹0.11.
In that period expenses were ₹71, interest cost ₹1 and tax ₹1. The next period listed, 2026-Jun, shows revenue of ₹80 and net profit of ₹1.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 74 | 80 | 75 | 69 | 58 | 73 | 59 | 64 | 73 | 77 | 81 | 65 | 61 | 62 | 93 |
| Expenses | 71 | 76 | 64 | 67 | 55 | 69 | 46 | 56 | 67 | 69 | 68 | 104 | 44 | 47 | 78 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 3 | 4 | 11 | 2 | 3 | 3 | 13 | 8 | 7 | 8 | 13 | -39 | 17 | 15 | 15 |
| Operating Profit % | 0.00% | 6.00% | 16.00% | 6.00% | 2.00% | 4.00% | 23.00% | 15.00% | 14.00% | 5.00% | 16.00% | -57.00% | 20.00% | 22.00% | 13.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 1 | 2 | 10 | 1 | 1 | 2 | 12 | 7 | 6 | 6 | 11 | -39 | 16 | 14 | 15 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 1 | 2 |
| Net Profit | 1 | 1 | 9 | 0 | 0 | 0 | 11 | 7 | 5 | 5 | 8 | -41 | 14 | 14 | 13 |
| EPS | 0.11 | 0.24 | 1.56 | 0.05 | 0.04 | 0.06 | 10.41 | 1.17 | 0.84 | 0.97 | 8.01 | -40.49 | 14.10 | 13.29 | 12.71 |
Balaxi Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen BALAXI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹5, and net cash flow was an outflow of ₹25.
Over the same period, investing activities used ₹21 and financing activities provided ₹0.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||
| Operating Activities | -5 | -35 | 5 | 6 | 34 | 0 | -14 | -2 |
| Investing Activities | -21 | -22 | -1 | -11 | -29 | -6 | 0 | 0 |
Financing and Net Cash | ||||||||
| Financing Activities | 0 | 34 | 30 | 26 | 0 | 4 | 18 | 0 |
| Net Cash Flow | -25 | -23 | 34 | 21 | 6 | -2 | 4 | -2 |
Balaxi Pharmaceuticals Shareholding Pattern Screener
See Balaxi Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Balaxi Pharmaceuticals promoter holding and ownership changes for BALAXI on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 65.99%, foreign institutions 0.00%, domestic institutions 2.56% and the public 24.41%, spread across 15,176 shareholders.
The shareholder count was 15,176 in 2026-Mar, compared with 14,682 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Apr |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 66.36% | 66.36% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.74% | 0.00% | 0.00% |
| DII Holding | 2.56% | 2.56% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 24.41% | 24.43% | 9.82% | 16.14% | 20.03% | 22.39% | 7.98% | 7.98% |
| Other Holding | 7.03% | 7.02% | 24.17% | 17.84% | 13.95% | 9.86% | 25.64% | 25.64% |
| Shareholder Count | 15,176 | 14,682 | 9,994 | 13,737 | 14,620 | 15,085 | 5,132 | 5,132 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Balaxi Pharmaceuticals. Balaxi Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.50 | 0.47% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Balaxi Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Balaxi Pharmaceuticals stock. Check BALAXI index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Balaxi Pharmaceuticals Market Events Screener - Corporate Actions
Get Balaxi Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Balaxi Pharmaceuticals stock events that may affect BALAXI share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 5, 2026, with a record date of August 5, 2026.
It is followed by Quarterly Result Announcement dated May 28, 2026 and Quarterly Result Announcement dated January 28, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-05 | 2026-08-05 | Quarterly Result Announcement | NA | -1.80% |
| 2026-05-28 | 2026-05-28 | Quarterly Result Announcement | NA | -14.25% |
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | 2.45% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -3.16% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -3.91% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -6.82% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 2.44% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | -1.03% |
| 2024-08-23 | 2024-08-23 | Annual General Meeting | NA | -5.24% |
| 2024-05-30 | 2024-05-30 | Split | 2:10 | 451.29% |
| 2022-07-01 | 2022-07-04 | Dividend | ₹ 0.50 /share | -13.13% |
| 2020-10-07 | 2020-10-07 | Change Of Name | NA | 0.00% |
Balaxi Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen BALAXI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 440,158 | 36.83 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 248,240 | 86.00 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 183,908 | 86.72 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 115,710 | 25.96 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 110,297 | 33.29 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,706 | 98.39 | 6,868 | 22.01% | 890 | 58.00 |
| Dr Reddys Laboratories | 102,666 | 32.77 | 35,059 | 3.90% | 4,158 | 69.59 |
| Mankind Pharma | 102,357 | 50.84 | 14,636 | 14.85% | 1,938 | 64.24 |
| Aurobindo Pharma | 96,589 | 26.41 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,287 | 16.97 | 29,039 | 26.75% | 5,356 | 34.02 |
Balaxi Pharmaceuticals Company Announcements - News & Reports Screener
Screen BALAXI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated September 7, 2026 and August 31, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Trading Window | - |
| 2026-09-07 | Updates | - |
| 2026-08-31 | General Updates | - |
| 2026-08-24 | Change in Director(s) | - |
| 2026-08-24 | Shareholders meeting | - |
| 2026-08-24 | Shareholders meeting | - |
| 2026-08-14 | Copy of Newspaper Publication | - |
| 2026-08-11 | Copy of Newspaper Publication | - |
| 2026-08-10 | Corrigendum | - |
| 2026-08-07 | Updates | - |
| 2026-08-06 | Investor Presentation | - |
| 2026-08-06 | Copy of Newspaper Publication | - |
| 2026-08-05 | Outcome of Board Meeting | - |
| 2026-08-05 | Outcome of Board Meeting | - |
| 2026-08-05 | Updates | - |
| 2026-08-01 | Copy of Newspaper Publication | - |
| 2026-07-31 | Updates | - |
| 2026-07-31 | Shareholders meeting | - |
| 2026-07-20 | Copy of Newspaper Publication | - |
| 2026-07-14 | Reply to Clarification- Financial results | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹22.77, within a 52-week range of ₹15.67 to ₹43.28. The P/E ratio is 52.32 and the P/B ratio is 0.51, with earnings per unit of ₹0.26. Market capitalisation stands at ₹125.87 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE. Key statistics were last updated on October 5, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.